Methods for in vivo identification of cancer initiating cells by multimodality reporter gene imaging
US-9220793-B2 · Dec 29, 2015 · US
Methods of treating disorders associated with protein aggregation
US9072772B2 · US · B2
| Field | Value |
|---|---|
| Publication number | US-9072772-B2 |
| Application number | US-201213463638-A |
| Country | US |
| Kind code | B2 |
| Filing date | May 3, 2012 |
| Priority date | Nov 5, 2009 |
| Publication date | Jul 7, 2015 |
| Grant date | Jul 7, 2015 |
How to read this patent
A practical reading order for non-experts. Skip the full description unless you need deep technical detail.
- Title
What the patent document calls the invention.
- Abstract
A short plain-language summary of the technical disclosure.
- Assignees and inventors
Who owns or filed the patent and who is credited as inventor.
- Key dates
Filing, priority, publication, and grant dates set the timeline.
- First independent claim
The legal scope of protection — read this for what is actually claimed.
- CPC / IPC classifications
Technology tags used to group this patent with similar filings.
- Citations and related patents
Prior art links and similar publications in this corpus.
Abstract
Official abstract text for this publication.
The present invention relates to methods of treatment of clinical disorders associated with protein aggregation comprising administering, to a subject, an effective amount of an anti-protein aggregate (“APA”) compound selected from the group consisting of pimozide, fluphenazine (e.g., fluphenazine hydrochloride), tamoxifen (e.g., tamoxifen citrate), taxol, cantharidin, cantharidic acid, salts thereof and their structurally related compounds. It is based, at least in part, on the discovery that each of the aforelisted compounds were able to promote degradation of aggregated ATZ protein in a Caenorhabditis elegans model system. According to the invention, treatment with one or more of these APA compounds may be used to ameliorate the symptoms and signs of AT deficiency as well as other disorders marked by protein aggregation, including, but not limited to, Alzheimer's Disease, Parkinson's Disease, and Huntington's Disease.
First claim
Opening claim text (preview).
We claim: 1. A method of reducing aggregated ATZ protein in a subject suffering from α1-antitrypsin deficiency comprising administering, to the subject, an amount of fluphenazine effective in reducing aggregated ATZ protein.
Assignees
Inventors
Classifications
containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone · CPC title
having four-membered rings, e.g. taxol · CPC title
Animal model, e.g. for test or diseases · CPC title
having six-membered rings, e.g. delta-lactones · CPC title
- A61K49/0008Primary
Screening agents using (non-human) animal models or transgenic animal models or chimeric hosts, e.g. Alzheimer disease animal model, transgenic model for heart failure · CPC title
Patent family
Related publications grouped by family.
External sources
Frequently asked questions
Answers are generated from the same data shown on this page.
- What does patent US9072772B2 cover?
- The present invention relates to methods of treatment of clinical disorders associated with protein aggregation comprising administering, to a subject, an effective amount of an anti-protein aggregate (“APA”) compound selected from the group consisting of pimozide, fluphenazine (e.g., fluphenazine hydrochloride), tamoxifen (e.g., tamoxifen citrate), taxol, cantharidin, cantharidic acid, salts t…
- Who is the assignee on this patent?
- Pak Stephen C, Perlmutter David Hirsch, Silverman Gary A, and 1 more
- What technology area does this patent fall under?
- Primary CPC classification A61K49/0008. Mapped technology areas include Human Necessities.
- When was this patent published?
- Publication date Tue Jul 07 2015 00:00:00 GMT+0000 (Coordinated Universal Time) (B2). Legal status and post-grant events are not shown on this page.
- What related patents are in patentsdb?
- We list 8 related publications on this page (citations in our corpus or others sharing the same primary CPC).